Document is current
Any future updates will be listed below
-
Authors
Bratman, Scott V. http://orcid.org/0000-0001-8610-4908
Yang, S. Y. Cindy
Iafolla, Marco A. J.
Liu, Zhihui
Hansen, Aaron R.
Bedard, Philippe L. http://orcid.org/0000-0002-6771-2999
Lheureux, Stephanie
Spreafico, Anna
Razak, Albiruni Abdul
Shchegrova, Svetlana
Louie, Maggie
Billings, Paul
Zimmermann, Bernhard http://orcid.org/0000-0002-5275-4571
Sethi, Himanshu
Aleshin, Alexey
Torti, Dax
Marsh, Kayla
Eagles, Jenna
Cirlan, Iulia http://orcid.org/0000-0002-1186-5435
Hanna, Youstina
Clouthier, Derek L.
Lien, Scott C.
Ohashi, Pamela S.
Xu, Wei
Siu, Lillian L. http://orcid.org/0000-0002-3500-0540
Pugh, Trevor J. http://orcid.org/0000-0002-8073-5888
-
Funding
Funding for this research was provided by:
Princess Margaret Cancer Foundation (Gattuso-Slaight Personalized Cancer Medicine Fund, BMO Chair in Precision Cancer Genomics)
UofT | Department of Medical Biophysics, University of Toronto (OSOTF Excellence Award)
Terry Fox Research Institute
Canada Research Chairs
Canada Foundation for Innovation (32383)
- License Information
-
More Information
Article History
Received: 7 March 2020
Accepted: 26 June 2020
First Online: 3 August 2020
Competing interests
: S.V.B. provides consultation for Bristol-Myers Squibb, receives research support from Nektar Therapeutics and is a coinventor on a patent application relating to circulating tumor DNA mutation detection technology (PCT/US2014/02502, licensed to Roche Molecular Diagnostics) and on a patent application relating to ctDNA methylation analysis technology (PCT/CA2018/000203). L.L.S. provides consultation for Merck (compensated), Pfizer (compensated), Celgene (compensated), AstraZeneca (compensated), Morphosys (compensated), Roche (compensated), GeneSeeq (compensated), Loxo (compensated), Oncorus (compensated), Symphogen (compensated), Seattle Genetics (compensated), GlaxoSmithKline (compensated), Voronoi (compensated), Treadwell Therapeutics (compensated), Arvinas (compensated), Tessa (compensated), Navire (compensated); receives research support (institutional) from Novartis, Bristol-Myers Squibb, Pfizer, Boerhinger-Ingelheim, GlaxoSmithKline, Roche/Genentech, Karyopharm, AstraZeneca/Medimmune, Merck, Celgene, Astellas, Bayer, Abbvie, Amgen, Symphogen, Intensity Therapeutics, Mirati, Shattucks and Avid; and is a stockholder in Agios (spouse) and Treadwell Therapeutics (spouse). S.S., M.L., P.B., B.Z., H.S. and A.A. are employees of Natera, Inc. T.J.P. provides consultation for Merck, Chrysalis Biomedical Advisors and the Canadian Pension Plan Investment Board, and receives research support from Roche.
